Aquestive Therapeutics, Inc.
AQST · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $12,807 | $10,003 | $8,720 | $11,867 |
| % Growth | 28% | 14.7% | -26.5% | – |
| Cost of Goods Sold | $4,506 | $4,561 | $3,652 | $4,520 |
| Gross Profit | $8,301 | $5,442 | $5,068 | $7,347 |
| % Margin | 64.8% | 54.4% | 58.1% | 61.9% |
| R&D Expenses | $4,530 | $4,105 | $5,361 | $4,917 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $15,250 | $12,705 | $19,072 | $16,009 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $19,780 | $16,810 | $24,433 | $20,926 |
| Operating Income | -$11,479 | -$11,368 | -$19,365 | -$13,579 |
| % Margin | -89.6% | -113.6% | -222.1% | -114.4% |
| Other Income/Exp. Net | -$3,967 | -$2,180 | -$3,565 | -$3,490 |
| Pre-Tax Income | -$15,446 | -$13,548 | -$22,930 | -$17,069 |
| Tax Expense | $0 | $0 | $0 | -$14 |
| Net Income | -$15,446 | -$13,548 | -$22,930 | -$17,055 |
| % Margin | -120.6% | -135.4% | -263% | -143.7% |
| EPS | -0.14 | -0.14 | -0.24 | -0.19 |
| % Growth | 0% | 41.7% | -26.3% | – |
| EPS Diluted | -0.14 | -0.14 | -0.24 | -0.19 |
| Weighted Avg Shares Out | 110,584 | 99,327 | 95,497 | 91,199 |
| Weighted Avg Shares Out Dil | 110,584 | 99,327 | 95,497 | 91,199 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2,096 | $713 | $734 |
| Interest Expense | $4,273 | $4,276 | $4,278 | $4,224 |
| Depreciation & Amortization | $139 | $140 | $2,889 | $147 |
| EBITDA | -$11,034 | -$9,132 | -$15,763 | -$12,698 |
| % Margin | -86.2% | -91.3% | -180.8% | -107% |